The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InXencor Inc. (NASDAQ: XNCR) has announced that Alexion, a subsidiary of AstraZeneca, has ceased making royalty payments in the United States for the drug Ultomiris. This unexpected development has forced Xencor to revise its revenue outlook as it assesses the financial implications of the payment halt. These royalties constitute a significant portion of Xencor's projected cash flow, and their suspension introduces immediate uncertainty into the company's financial guidance. Analysts consider this move a bearish signal for the stock, as it may lead to protracted legal or commercial disputes. Xencor is currently evaluating its options under the existing licensing agreement to address the loss of income. Investors are expected to remain cautious until further clarity is provided regarding the duration and impact of this royalty dispute.